Propargylamine: an important moiety in drug discovery

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Paal C, Heupel A. Ueber einige ungesättigte Amine der aliphatischen Reihe. Ber. Dtsch. Chem. Ges. 24(2), 3035–3048 (1891).
  Google Scholar
• 2. Lauder K, Toscani A, Scalacci N, Castagnolo D. Synthesis and reactivity of propargylamines in organic chemistry. Chem. Rev. 117(24), 14091–14200 (2017). •• Extensive and complete review of the relevance of propargylamine and its derivatives in organic synthesis.
  Medline CASGoogle Scholar
• 3. Balamurugan R, Chien CC, Wu KM, Chiu YH, Liu JH. A depropargylation-triggered fluorescence “turn-on” probe for the detection of Pd2+ based on a bispropargylamine–rhodamine conjugate. Analyst 138(5), 1564–1569 (2013).
  Medline CASGoogle Scholar
• 4. Wünsch M, Senger J, Schultheisz P et al. Structure-activity relationship of propargylamine-based HDAC inhibitors. ChemMedChem 12(24), 2044–2053 (2017).
  Medline CASGoogle Scholar
• 5. Zindo FT, Joubert J, Malan SF. Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond. Future Med. Chem. 7(5), 609–629 (2015).
  CASGoogle Scholar
• 6. Nguyen VT, Pandith A, Seo YJ. Propargylamine-selective dual fluorescence turn-on method for post-synthetic labeling of DNA. Chem. Commun. 56(21), 3199–3202 (2020).
  Medline CASGoogle Scholar
• 7. Huleatt PB, Khoo ML, Chua YY et al. Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease. J. Med. Chem. 58(3), 1400–1419 (2015).
  Medline CASGoogle Scholar
• 8. Durden DA, Dyck LE, Davis BA, Liu YD, Boulton AA. Metabolism and pharmacokinetics, in the rat, of (R)-N-(2-heptyl)methyl-propargylamine (R-2HMP), a new potent monoamine oxidase inhibitor and antiapoptotic agent. Drug Metab. Dispos. 28(2), 147–154 (2000).
  Medline CASGoogle Scholar
• 9. Aprile S, Canavesi R, Matucci R, Bellucci C, Del Grosso E, Grosa G. New insights in the metabolism of oxybutynin: evidence of N-oxidation of propargylamine moiety and rearrangement to enaminoketone. Xenobiotica 48(5), 478–487 (2018). • Provides evidence about potential metabolic transformations that the propargylamine moiety may undergo.
  Medline CASGoogle Scholar
• 10. Talele TT. Acetylene group, friend or foe in medicinal chemistry. J. Med. Chem. 63(11), 5625–5663 (2020). • Highlights the advantages and drawbacks of the acetylene group in medicinal chemistry.
  Medline CASGoogle Scholar
• 11. Finberg JPM. Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease. J. Neural Transm. 126(4), 433–448 (2019).
  MedlineGoogle Scholar
• 12. Carradori S, Secci D, Petzer JP. MAO inhibitors and their wider applications: a patent review. Expert Opin. Ther. Pat. 28(3), 211–226 (2018).
  Medline CASGoogle Scholar
• 13. Tripathi AC, Upadhyay S, Paliwal S, Saraf SK. Privileged scaffolds as MAO inhibitors: retrospect and prospects. Eur. J. Med. Chem. 145(10), 445–497 (2018).
  Medline CASGoogle Scholar
• 14. Kay CWM, El Mkami H, Molla G, Pollegioni L, Ramsay RR. Characterization of the covalently bound anionic flavin radical in monoamine oxidase A by electron paramagnetic resonance. J. Am. Chem. Soc. 129(51), 16091–16097 (2007).
  Medline CASGoogle Scholar
• 15. Ramsay RR, Albreht A. Questions in the chemical enzymology of MAO. Chemistry 3(3), 959–978 (2021).
  Google Scholar
• 16. Swett LR, Martin WB, Taylor JD, Everett GM, Wykes AA, Gladish YC. Structure-activity relations in the pargyline series. Ann. NY Acad. Sci. 107(3), 891–898 (1963).
  Medline CASGoogle Scholar
• 17. Huebner CF, Donoghue EM, Plummer AJ, Furness PA. N-Methyl-N-2-propynyl-1-indanamine. A potent monoamine oxidase inhibitor. J. Med. Chem. 9(6), 830–832 (1966).
  Medline CASGoogle Scholar
• 18. Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch. Int. Pharmacodyn. Ther. 155(1), 154–164 (1965).
  Medline CASGoogle Scholar
• 19. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17(7), 1285–1297 (1968).
  Medline CASGoogle Scholar
• 20. Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 5, 393–408 (1972).
  Medline CASGoogle Scholar
• 21. Gaál J, Hermecz I. Medicinal chemistry of present and future MAO-B inhibitors. In: Inhibitors of Monoamine Oxidase B. Szelenyi I (Eds). Birkhäuser, Basel, Switzerland 75– 108 (1993).
  Google Scholar
• 22. Foley P, Gerlach M, Youdim MB, Riederer P. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat. Disord. 6(1), 25–47 (2000).
  Medline CASGoogle Scholar
• 23. Tandarić T, Vianello R. Computational insight into the mechanism of the irreversible inhibition of monoamine oxidase enzymes by the antiparkinsonian propargylamine inhibitors rasagiline and selegiline. ACS Chem. Neurosci. 10(8), 3532–3542 (2019).
  Medline CASGoogle Scholar
• 24. Ramsay RR, Albreht A. Kinetics, mechanism, and inhibition of monoamine oxidase. J. Neural Transm. (Vienna) 125(11), 1659–1683 (2018).
  Medline CASGoogle Scholar
• 25. Ramsay RR, Basile L, Maniquet A et al. Parameters for irreversible inactivation of monoamine oxidase. Molecules 25(24), 5908 (2020).
  Medline CASGoogle Scholar
• 26. Albreht A, Vovk I, Mavri J, Marco-Contelles J, Ramsay RR. Evidence for a cyanine link between propargylamine drugs and monoamine oxidase clarifies the inactivation mechanism. Front. Chem. 6, 169 (2018). •• Proposes a mechanism of action for propargylamine-based monoamine oxidase inhibitors to act as suicide inhibitors, irreversibly binding to flavin adenine dinucleotide.
  MedlineGoogle Scholar
• 27. Binda C, Hubalek F, Li M, Castagnoli N, Edmondson DE, Mattevi A. Structure of the human mitochondrial monoamine oxidase B: new chemical implications for neuroprotectant drug design. Neurology 67(2 Suppl. 7), S5–S7 (2006).
  Medline CASGoogle Scholar
• 28. Binda C, Hubálek F, Li M et al. Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. J. Med. Chem. 48(26), 8148–8154 (2005).
  Medline CASGoogle Scholar
• 29. Knez D, Colettis N, Iacovino LG et al. Stereoselective activity of 1-propargyl-4-styrylpiperidine-like analogues that can discriminate between monoamine oxidase isoforms A and B. J. Med. Chem. 63(3), 1361–1387 (2020). • Focuses on the development of a pair of cis/trans isomers that can discriminate between both monoamine oxidase-A and B isoforms.
  Medline CASGoogle Scholar
• 30. Matos MJ, Herrera Ibatá DM, Uriarte E, Viña D. Coumarin-rasagiline hybrids as potent and selective hMAO-B inhibitors, antioxidants, and neuroprotective agents. ChemMedChem 15(6), 532–538 (2020).
  Medline CASGoogle Scholar
• 31. De Deurwaerdère P, Binda C, Corne R et al. Comparative analysis of the neurochemical profile and MAO inhibition properties of N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine. ACS Chem. Neurosci. 8(5), 1026–1035 (2017).
  MedlineGoogle Scholar
• 32. Krátký M, Vu QA, Štěpánková Š et al. Novel propargylamine-based inhibitors of cholinesterases and monoamine oxidases: synthesis, biological evaluation and docking study. Bioorg. Chem. 116, 105301 (2021).
  Medline CASGoogle Scholar
• 33. Narayanaswami V, Drake LR, Brooks AF et al. Classics in neuroimaging: development of PET tracers for imaging monoamine oxidases. ACS Chem. Neurosci. 10(4), 1867–1871 (2019).
  Medline CASGoogle Scholar
• 34. Cavalli A, Bolognesi ML, Minarini A. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 51(3), 347–372 (2008).
  Medline CASGoogle Scholar
• 35. Rodríguez-Enríquez F, Viña D, Uriarte E, Laguna R, Matos MJ. 7-Amidocoumarins as multitarget agents against neurodegenerative diseases: substitution pattern modulation. ChemMedChem 16(1), 179–186 (2020).
  MedlineGoogle Scholar
• 36. Matos MJ, Janeiro P, González-Franco RM et al. Synthesis, pharmacological study and docking calculations of new benzo[f]coumarin derivatives as dual inhibitors of enzymatic systems involved in neurodegenerative diseases. Future Med. Chem. 6(4), 371–383 (2014).
  CASGoogle Scholar
• 37. Matos MJ, Mura F, Vazquez-Rodriguez S et al. Study of coumarin-resveratrol hybrids as potent antioxidant compounds. Molecules 20(2), 3290–3308 (2015).
  MedlineGoogle Scholar
• 38. Sterling J, Herzig Y, Goren T et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem. 45(24), 5260–5279 (2002). •• Introduces a strategy for dual monoamine oxidase and cholinesterase inhibition.
  Medline CASGoogle Scholar
• 39. Weinreb O, Amit T, Bar-Am O, Youdim MBH. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr. Drug Targets 13(4), 483–494 (2012).
  Medline CASGoogle Scholar
• 40. Avraham Pharmaceuticals Ltd Avraham Pharmaceuticals Ltd. Safety and efficacy study of ladostigil in mild to moderate probable Alzheimer's disease.. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01354691 (Accessed 22 February 2022).
  Google Scholar
• 41. Bolea I, Juárez-Jiménez J, de los Ríos C et al. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem. 54(24), 8251–8270 (2011).
  Medline CASGoogle Scholar
• 42. Wang L, Esteban G, Ojima M et al. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem. 80, 543–561 (2014).
  Medline CASGoogle Scholar
• 43. Xu Y, Wang H, Li X et al. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 143, 33–47 (2018).
  Medline CASGoogle Scholar
• 44. Xu Y, Zhang J, Wang H et al. Rational design of novel selective dual-target inhibitors of acetylcholinesterase and monoamine oxidase B as potential anti-Alzheimer's disease agents. ACS Chem. Neurosci. 10(1), 482–496 (2019).
  Medline CASGoogle Scholar
• 45. Liu W, Lang M, Youdim MBH et al. Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease. Neuropharmacology 109, 376–385 (2016).
  Medline CASGoogle Scholar
• 46. Košak U, Knez D, Coquelle N et al. N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: potential multifunctional anti-Alzheimer's agents. Bioorg. Med. Chem. 25(2), 633–645 (2017).
  Medline CASGoogle Scholar
• 47. Baranyi M, Porceddu PF, Gölöncsér F et al. Novel (hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease. Mol. Neurodegener. 11(1), 6 (2016).
  MedlineGoogle Scholar
• 48. Marco-Contelles J, Unzeta M, Bolea I et al. ASS234, as a new multi-target directed propargylamine for Alzheimer's disease therapy. Front. Neurosci. 10, 294 (2016).
  MedlineGoogle Scholar
• 49. Ramos E, Romero A, Marco-Contelles J, del Pino J. Upregulation of antioxidant enzymes by ASS234, a multitarget directed propargylamine for Alzheimer's disease therapy. CNS Neurosci. Ther. 22(9), 799–802 (2016).
  Medline CASGoogle Scholar
• 50. Criado M, Mulet J, Sala F et al. N-Benzylpiperidine derivatives as A7 nicotinic receptor antagonists. ACS Chem. Neurosci. 7(8), 1157–1165 (2016).
  Medline CASGoogle Scholar
• 51. Zindo FT, Malan SF, Omoruyi SI, Enogieru AB, Ekpo OE, Joubert J. Design, synthesis and evaluation of pentacycloundecane and hexacycloundecane propargylamine derivatives as multifunctional neuroprotective agents. Eur. J. Med. Chem. 163, 83–94 (2019).
  Medline CASGoogle Scholar
• 52. Yogev-Falach M, Amit T, Bar-Am O, Youdim MBH. The importance of propargylamine moiety in the anti- Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J. 17(15), 2325–2327 (2003).
  Medline CASGoogle Scholar
• 53. Gal S, Fridkin M, Amit T, Zheng H, M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-Ab inhibitory activity for Parkinson's disease. In: Parkinson's Disease and Related Disorders. Youdim MBHRiederer PReichmann HGerlach M (Eds). Springer, Vienna, Austria 447–456 (2006).
  Google Scholar
• 54. Youdim MBH. Multi-target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and M30 derived from rasagiline. Exp. Neurobiol. 22(1), 1–10 (2013).
  MedlineGoogle Scholar
• 55. Duro-Castano A, Borrás C, Herranz-Pérez V et al. Targeting Alzheimer's disease with multimodal polypeptide-based nanoconjugates. Sci. Adv. 7(13), eabf9180 (2021).
  Medline CASGoogle Scholar
• 56. Silalai P, Pruksakorn D, Chairoungdua A, Suksen K, Saeeng R. Synthesis of propargylamine mycophenolate analogues and their selective cytotoxic activity towards neuroblastoma SH-SY5Y cell line. Bioorg. Med. Chem. Lett. 45, 128135 (2021).
  Medline CASGoogle Scholar
• 57. Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. J. Neural Transm. 120(3), 435–444 (2012). • Identifies a certain selectivity toward neuroblastoma cell lines over normal cells observed in compounds bearing the propargylamine moiety, such as rasagiline and selegiline.
  MedlineGoogle Scholar
• 58. Martinez-Amezaga M, Giordano RA, Prada-Gori DN et al. Synthesis of propargylamines via the A³ multicomponent reaction and their biological evaluation as potential anticancer agents. Org. Biomol. Chem. 18(13), 2475–2486 (2020).
  Medline CASGoogle Scholar
• 59. Csuk R, Nitsche C, Sczepek R, Schwarz S, Siewert B. Synthesis of antitumor-active betulinic acid-derived hydroxypropargylamines by copper-catalyzed Mannich reactions. Arch. Pharm. Pharm. Med. Chem. 346(3), 232–246 (2013).
  Medline CASGoogle Scholar
• 60. Wünsch M, Senger J, Schultheisz P et al. Structure-activity relationship of propargylamine-based HDAC inhibitors. ChemMedChem 12(24), 2044–2053 (2017).
  Medline CASGoogle Scholar
• 61. Schmitt ML, Hauser AT, Carlino L et al. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity. J. Med. Chem. 56(18), 7334–7342 (2013).
  Medline CASGoogle Scholar
• 62. Versini A, Colombeau L, Hienzsch A et al. Salinomycin derivatives kill breast cancer stem cells by lysosomal iron targeting. Chem. Eur. J. 26(33), 7416–7424 (2020).
  Medline CASGoogle Scholar
• 63. Dziuba D, Pohl R, Hocek M. Polymerase synthesis of DNA labelled with benzylidene cyanoacetamide-based fluorescent molecular rotors: fluorescent light-up probes for DNA-binding proteins. Chem. Commun. 51(23), 4880–4882 (2015).
  Medline CASGoogle Scholar
• 64. Antoszczak M, Steverding D, Sulik M, Janczak J, Huczyński A. Anti-trypanosomal activity of doubly modified salinomycin derivatives. Eur. J. Med. Chem. 173, 90–98 (2019).
  Medline CASGoogle Scholar
• 65. Kögler M, Vanderhoydonck B, De Jonghe S et al. Synthesis and evaluation of 5-substituted 2′-deoxyuridine monophosphate analogues as inhibitors of flavin-dependent thymidylate synthase in Mycobacterium tuberculosis. J. Med. Chem. 54(13), 4847–4862 (2011).
  Medline CASGoogle Scholar
• 66. Jones TR, Varney MD, Webber SE et al. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase. J. Med. Chem. 39(4), 904–917 (1996).
  Medline CASGoogle Scholar
• 67. Villemagne B, Flipo M, Blondiaux N et al. Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. J. Med. Chem. 57(11), 4876–4888 (2014).
  Medline CASGoogle Scholar
• 68. Denton TT, Srivastava P, Xia Z et al. Identification of the 4-position of 3-alkynyl and 3-heteroaromatic substituted pyridine methanamines as a key modification site eliciting increased potency and enhanced selectivity for cytochrome P-450 2A6 inhibition. J. Med. Chem. 61(16), 7065–7086 (2018).
  Medline CASGoogle Scholar
• 69. Hein JE, Fokin VV. Copper-catalyzed azide–alkyne cycloaddition (CuAAC) and beyond: new reactivity of copper(I) acetylides. Chem. Soc. Rev. 39(4), 1302 (2010). •• Exemplifies an important bio-orthogonal click chemistry reaction that may be accessible to relevant compounds by introducing a propargylamine residue.
  Medline CASGoogle Scholar
• 70. He Y, Liang Y, Wang D. The highly sensitive and facile colorimetric detection of the glycidyl azide polymer based on propargylamine functionalized gold nanoparticles using click chemistry. Chem. Commun. 51(60), 12092–12094 (2015).
  Medline CASGoogle Scholar
• 71. Baranyai Z, Reich D, Vágner A et al. Shortcut to high-affinity Ga-68 and Cu-64 radiopharmaceuticals: one-pot click chemistry trimerisation on the TRAP platform. Dalton Trans. 44(24), 11137–11146 (2015).
  Medline CASGoogle Scholar
• 72. Jung-Jou M, Chen X, Swamy KMK et al. Highly selective fluorescent probe for Au3+ based on cyclization of propargylamide. Chem. Commun. 46, 7218 (2009).
  Google Scholar
• 73. Young-Choi J, Kim GH, Guo Z et al. Highly selective ratiometric fluorescent probe for Au3+ and its application to bioimaging. Biosens. Bioelectron. 49, 438–441 (2013).
  Medline CASGoogle Scholar
• 74. Gnaccarini C, Ben-Tahar W, Mulani A et al. Site-specific protein propargylation using tissue transglutaminase. Org. Biomol. Chem. 10(27), 5258 (2012).
  Medline CASGoogle Scholar
• 75. Thomas SR, Casini A. Gold compounds for catalysis and metal-mediated transformations in biological systems. Curr. Opin. Chem. Biol. 55, 103–110 (2020).
  Medline CASGoogle Scholar
• 76. He Y, Liang Y, Wang D. The highly sensitive and facile colorimetric detection of the glycidyl azide polymer based on propargylamine functionalized gold nanoparticles using click chemistry. Chem. Commun. 51(60), 12092–12094 (2015).
  Medline CASGoogle Scholar
• 77. Cohen M, Hadjivassiliou H, Taunton J. A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nat. Chem. Biol. 3, 156–160 (2007).
  Medline CASGoogle Scholar
• 78. Oliveira JR, Martins MCL, Mafra L, Gomes P. Synthesis of an O-alkynyl-chitosan and its chemoselective conjugation with a PEG-like amino-azide through click chemistry. Carbohydr. Polym. 87(1), 240–249 (2012).
  Medline CASGoogle Scholar
• 79. Belov AS, Prikhod'ko AI, Novikov VV, Vologzhanina AV, Bubnov YN, Voloshin YZ. First “click” synthesis of the ribbed-functionalized metal clathrochelates: cycloaddition of benzyl azide to propargylamine iron(II) macrobicycle and the unexpected transformations of the resulting cage complex. Eur. J. Inorg. Chem. 2012(28), 4507–4514 (2012).
  CASGoogle Scholar